Comparison of atogepant vs rimegepant in refractory chronic migraine: A retrospective analysis

被引：0
|
作者：
Baek, William [1 ]
机构：
[1] Parkside Med Grp, Neurol, Upland, CA USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2023年 / 455卷
关键词：
D O I：
10.1016/j.jns.2023.121619
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
121619
引用
收藏
页数：1
相关论文
共 50 条
  • [1] High-responder rates of atogepant in refractory chronic migraine: A retrospective analysis
    Baek, William
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [2] Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
    Ailani, J.
    Gandhi, P.
    Lalla, A.
    Singh, R. B. Halker
    McAllister, P.
    Smith, J. H.
    Dabruzzo, B.
    Chalermpalanupap, N.
    Nahas, S. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [3] Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine
    Silberstein, S. D.
    Cohen, J. M.
    Driessen, M.
    Muresan, B.
    Krasenbaum, L. J.
    Johnston, A.
    Seminerio, M. J.
    Carr, K.
    Akcicek, H.
    Dever, J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 266 - 266
  • [4] Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine
    Silberstein, S. D.
    Cohen, J. M.
    Driessen, M.
    Muresan, B.
    Krasenbaum, L. J.
    Johnston, A.
    Seminerio, M. J.
    Carr, K.
    Akcicek, H.
    Dever, J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [5] Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
    Wells-Gatnik, William David
    Pellesi, Lanfranco
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1107 - 1117
  • [6] Lidocaine infusions for refractory chronic migraine: a retrospective analysis
    Schwenk, Eric S.
    Walter, Aaron
    Torjman, Marc C.
    Mukhtar, Sarah
    Patel, Harsh T.
    Nardone, Bryan
    Sun, George
    Thota, Bhavana
    Lauritsen, Clinton G.
    Silberstein, Stephen D.
    REGIONAL ANESTHESIA AND PAIN MEDICINE, 2022, 47 (07) : 408 - 413
  • [7] Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
    Ailani, Jessica
    Gandhi, Pranav
    Lalla, Anjana
    Singh, Rashmi Halker
    McAllister, Peter
    Smith, Jonathan H.
    Dabruzzo, Brett
    Chalermpalanupap, Natty
    Kelton, Kari
    Nahas, Stephanie J.
    HEADACHE, 2024, 64 (10): : 1253 - 1263
  • [8] Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Singh, Rashmi B. Halker
    Duan, Molly
    Dupont-Benjamin, Laure
    Hemstock, Matthew
    Voller, Corey
    McAllister, Peter
    Nahas, Stephanie J.
    Gandhi, Pranav
    Ailani, Jessica
    CEPHALALGIA, 2024, 44 (02)
  • [9] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Duan, Molly
    Hemstock, Matthew
    Voller, Corey
    Gandhi, Pranav
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2023, 43 (1supp) : 258 - 260
  • [10] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, C.
    Onishchenko, K.
    Duan, M.
    Hemstock, M.
    Voller, C.
    Gandhi, P.
    Dupont-Benjamin, L.
    HEADACHE, 2023, 63 : 122 - 123
12345